AB0483 Cutaneous adverse events related to TNF[alpha] blockers in patients with chronic inflammatory arthritis

AB0483 Cutaneous adverse events related to TNF[alpha] blockers in patients with chronic inflammatory arthritis

Background TNFα blockers are effective options for the treatment of different forms of chronic inflammatory arthritis (CIA). However, these drugs are associated with a greater frequency of adverse events, especially infectious and allergic events. Objectives To evaluate the incidence and the main ri...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2013-06, Vol.71, p.665
Hauptverfasser: Machado, NP, Pinheiro, MM, Reis Neto, ET, Melo, MR, Pereira, DF, Porro, A, Ciconelli, RM
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 665
container_title Annals of the rheumatic diseases
container_volume 71
creator Machado, NP
Pinheiro, MM
Reis Neto, ET
Melo, MR
Pereira, DF
Porro, A
Ciconelli, RM
description Background TNFα blockers are effective options for the treatment of different forms of chronic inflammatory arthritis (CIA). However, these drugs are associated with a greater frequency of adverse events, especially infectious and allergic events. Objectives To evaluate the incidence and the main risk factors associated with cutaneous adverse events (CAE) in patients with CIA following anti-TNF therapy. Methods A total of 257 patients with active CIA and under using TNFα blockers were analyzed - 158 with rheumatoid arthritis (RA), 87 with ankylosing spondylitis(AS) and 12 with psoriatic arthritis (PA) - in a prospective analysis from January 2005 to December 2009. Patients with active or chronic infection, including hepatitis B, hepatitis C or human immunodeficiency virus, and those with overlap of other autoimmune rheumatic diseases were excluded. Anthropometric, socioeconomic, demographic and clinical data were evaluated, including DAS28, BASDAI and PASI. Skin conditions were evaluated by two dermatologists and a biopsy was performed in cases of doubt. Infectious events were classified as viral, parasitic, fungal or bacterial, depending on the clinical condition or identification of the etiological agent. Associations between CAE and clinical, demographic and epidemiological variables were determined using the chi-square test and logistic regression analyses for the identification of risk factors. The level of significance was set at 5% (p
doi_str_mv 10.1136/annrheumdis-2012-eular.483
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1777975955</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4008650261</sourcerecordid><originalsourceid>FETCH-proquest_journals_17779759553</originalsourceid><addsrcrecordid>eNqNystOwzAUBFALgUR4_MMVrFPs5uFkCRVVV6y6Q1V1m9zKLo4d_Cji77EQH8BqNDOHsQfBF0JU7RNa6xWladShXHKxLCkZ9Iu6qy5YIeq2y2vLL1nBOa_Kum_lNbsJ4ZQr70RXMPv8wrOGVYpoyaUAOJ7JBwI6k40BPBmMNEJ0sH1bv6OZFe7gYNzwkRloCzNG_Uu_dFQwKO-sHvJxNDhNGJ3_BvRReR11uGNXRzSB7v_ylj2uX7erTTl795koxP3JJW_ztRdSyl42fdNU_1M_bCBVqw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777975955</pqid></control><display><type>article</type><title>AB0483 Cutaneous adverse events related to TNF[alpha] blockers in patients with chronic inflammatory arthritis</title><source>BMJ Journals - NESLi2</source><creator>Machado, NP ; Pinheiro, MM ; Reis Neto, ET ; Melo, MR ; Pereira, DF ; Porro, A ; Ciconelli, RM</creator><creatorcontrib>Machado, NP ; Pinheiro, MM ; Reis Neto, ET ; Melo, MR ; Pereira, DF ; Porro, A ; Ciconelli, RM</creatorcontrib><description>Background TNFα blockers are effective options for the treatment of different forms of chronic inflammatory arthritis (CIA). However, these drugs are associated with a greater frequency of adverse events, especially infectious and allergic events. Objectives To evaluate the incidence and the main risk factors associated with cutaneous adverse events (CAE) in patients with CIA following anti-TNF therapy. Methods A total of 257 patients with active CIA and under using TNFα blockers were analyzed - 158 with rheumatoid arthritis (RA), 87 with ankylosing spondylitis(AS) and 12 with psoriatic arthritis (PA) - in a prospective analysis from January 2005 to December 2009. Patients with active or chronic infection, including hepatitis B, hepatitis C or human immunodeficiency virus, and those with overlap of other autoimmune rheumatic diseases were excluded. Anthropometric, socioeconomic, demographic and clinical data were evaluated, including DAS28, BASDAI and PASI. Skin conditions were evaluated by two dermatologists and a biopsy was performed in cases of doubt. Infectious events were classified as viral, parasitic, fungal or bacterial, depending on the clinical condition or identification of the etiological agent. Associations between CAE and clinical, demographic and epidemiological variables were determined using the chi-square test and logistic regression analyses for the identification of risk factors. The level of significance was set at 5% (p&lt;0.05). Results After 60 months of follow up, 71 CAE (73.85/1000 patients-year) were observed, especially related to allergic and immune-mediated phenomena (37.93/1000 patients-year), followed by infectious conditions (34.71/1000 patients-year), including bacterial (47.1%), parasitic (23.5%), fungal (20.6%) and viral (8.8%). Three CAE (4.22%) were classified as serious. The main risk factors significantly associated with CAE were advanced age (OR=1.09; 95%CI: 1.05-3.72), female gender (OR=2.8; 95%CI: 1.90-5.63), diagnosis of RA (OR=1.9; 95%CI: 1.11-4.62), disease activity [DAS28: OR=1.5; 95%CI: 1.2-4.68 or BASDAI: OR=1.1; 95%CI: 1.02-6.37], use of IFX (OR=1.6; 95%CI: 1.06-4.01), independently from time since diagnosis. These reactions generally had a good prognosis after withdrawal of medications and specific treatment. Conclusions Our results demonstrate that the skin is an important site affected by adverse reactions following TNFα blockers. References Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-975. van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70: 905-911. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68: 1387-1394. Disclosure of Interest None Declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2012-eular.483</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: Elsevier Limited</publisher><ispartof>Annals of the rheumatic diseases, 2013-06, Vol.71, p.665</ispartof><rights>Copyright: 2013 (c) 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Machado, NP</creatorcontrib><creatorcontrib>Pinheiro, MM</creatorcontrib><creatorcontrib>Reis Neto, ET</creatorcontrib><creatorcontrib>Melo, MR</creatorcontrib><creatorcontrib>Pereira, DF</creatorcontrib><creatorcontrib>Porro, A</creatorcontrib><creatorcontrib>Ciconelli, RM</creatorcontrib><title>AB0483 Cutaneous adverse events related to TNF[alpha] blockers in patients with chronic inflammatory arthritis</title><title>Annals of the rheumatic diseases</title><description>Background TNFα blockers are effective options for the treatment of different forms of chronic inflammatory arthritis (CIA). However, these drugs are associated with a greater frequency of adverse events, especially infectious and allergic events. Objectives To evaluate the incidence and the main risk factors associated with cutaneous adverse events (CAE) in patients with CIA following anti-TNF therapy. Methods A total of 257 patients with active CIA and under using TNFα blockers were analyzed - 158 with rheumatoid arthritis (RA), 87 with ankylosing spondylitis(AS) and 12 with psoriatic arthritis (PA) - in a prospective analysis from January 2005 to December 2009. Patients with active or chronic infection, including hepatitis B, hepatitis C or human immunodeficiency virus, and those with overlap of other autoimmune rheumatic diseases were excluded. Anthropometric, socioeconomic, demographic and clinical data were evaluated, including DAS28, BASDAI and PASI. Skin conditions were evaluated by two dermatologists and a biopsy was performed in cases of doubt. Infectious events were classified as viral, parasitic, fungal or bacterial, depending on the clinical condition or identification of the etiological agent. Associations between CAE and clinical, demographic and epidemiological variables were determined using the chi-square test and logistic regression analyses for the identification of risk factors. The level of significance was set at 5% (p&lt;0.05). Results After 60 months of follow up, 71 CAE (73.85/1000 patients-year) were observed, especially related to allergic and immune-mediated phenomena (37.93/1000 patients-year), followed by infectious conditions (34.71/1000 patients-year), including bacterial (47.1%), parasitic (23.5%), fungal (20.6%) and viral (8.8%). Three CAE (4.22%) were classified as serious. The main risk factors significantly associated with CAE were advanced age (OR=1.09; 95%CI: 1.05-3.72), female gender (OR=2.8; 95%CI: 1.90-5.63), diagnosis of RA (OR=1.9; 95%CI: 1.11-4.62), disease activity [DAS28: OR=1.5; 95%CI: 1.2-4.68 or BASDAI: OR=1.1; 95%CI: 1.02-6.37], use of IFX (OR=1.6; 95%CI: 1.06-4.01), independently from time since diagnosis. These reactions generally had a good prognosis after withdrawal of medications and specific treatment. Conclusions Our results demonstrate that the skin is an important site affected by adverse reactions following TNFα blockers. References Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-975. van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70: 905-911. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68: 1387-1394. Disclosure of Interest None Declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNystOwzAUBFALgUR4_MMVrFPs5uFkCRVVV6y6Q1V1m9zKLo4d_Cji77EQH8BqNDOHsQfBF0JU7RNa6xWladShXHKxLCkZ9Iu6qy5YIeq2y2vLL1nBOa_Kum_lNbsJ4ZQr70RXMPv8wrOGVYpoyaUAOJ7JBwI6k40BPBmMNEJ0sH1bv6OZFe7gYNzwkRloCzNG_Uu_dFQwKO-sHvJxNDhNGJ3_BvRReR11uGNXRzSB7v_ylj2uX7erTTl795koxP3JJW_ztRdSyl42fdNU_1M_bCBVqw</recordid><startdate>20130601</startdate><enddate>20130601</enddate><creator>Machado, NP</creator><creator>Pinheiro, MM</creator><creator>Reis Neto, ET</creator><creator>Melo, MR</creator><creator>Pereira, DF</creator><creator>Porro, A</creator><creator>Ciconelli, RM</creator><general>Elsevier Limited</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20130601</creationdate><title>AB0483 Cutaneous adverse events related to TNF[alpha] blockers in patients with chronic inflammatory arthritis</title><author>Machado, NP ; Pinheiro, MM ; Reis Neto, ET ; Melo, MR ; Pereira, DF ; Porro, A ; Ciconelli, RM</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_17779759553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Machado, NP</creatorcontrib><creatorcontrib>Pinheiro, MM</creatorcontrib><creatorcontrib>Reis Neto, ET</creatorcontrib><creatorcontrib>Melo, MR</creatorcontrib><creatorcontrib>Pereira, DF</creatorcontrib><creatorcontrib>Porro, A</creatorcontrib><creatorcontrib>Ciconelli, RM</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Machado, NP</au><au>Pinheiro, MM</au><au>Reis Neto, ET</au><au>Melo, MR</au><au>Pereira, DF</au><au>Porro, A</au><au>Ciconelli, RM</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AB0483 Cutaneous adverse events related to TNF[alpha] blockers in patients with chronic inflammatory arthritis</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2013-06-01</date><risdate>2013</risdate><volume>71</volume><spage>665</spage><pages>665-</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Background TNFα blockers are effective options for the treatment of different forms of chronic inflammatory arthritis (CIA). However, these drugs are associated with a greater frequency of adverse events, especially infectious and allergic events. Objectives To evaluate the incidence and the main risk factors associated with cutaneous adverse events (CAE) in patients with CIA following anti-TNF therapy. Methods A total of 257 patients with active CIA and under using TNFα blockers were analyzed - 158 with rheumatoid arthritis (RA), 87 with ankylosing spondylitis(AS) and 12 with psoriatic arthritis (PA) - in a prospective analysis from January 2005 to December 2009. Patients with active or chronic infection, including hepatitis B, hepatitis C or human immunodeficiency virus, and those with overlap of other autoimmune rheumatic diseases were excluded. Anthropometric, socioeconomic, demographic and clinical data were evaluated, including DAS28, BASDAI and PASI. Skin conditions were evaluated by two dermatologists and a biopsy was performed in cases of doubt. Infectious events were classified as viral, parasitic, fungal or bacterial, depending on the clinical condition or identification of the etiological agent. Associations between CAE and clinical, demographic and epidemiological variables were determined using the chi-square test and logistic regression analyses for the identification of risk factors. The level of significance was set at 5% (p&lt;0.05). Results After 60 months of follow up, 71 CAE (73.85/1000 patients-year) were observed, especially related to allergic and immune-mediated phenomena (37.93/1000 patients-year), followed by infectious conditions (34.71/1000 patients-year), including bacterial (47.1%), parasitic (23.5%), fungal (20.6%) and viral (8.8%). Three CAE (4.22%) were classified as serious. The main risk factors significantly associated with CAE were advanced age (OR=1.09; 95%CI: 1.05-3.72), female gender (OR=2.8; 95%CI: 1.90-5.63), diagnosis of RA (OR=1.9; 95%CI: 1.11-4.62), disease activity [DAS28: OR=1.5; 95%CI: 1.2-4.68 or BASDAI: OR=1.1; 95%CI: 1.02-6.37], use of IFX (OR=1.6; 95%CI: 1.06-4.01), independently from time since diagnosis. These reactions generally had a good prognosis after withdrawal of medications and specific treatment. Conclusions Our results demonstrate that the skin is an important site affected by adverse reactions following TNFα blockers. References Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-975. van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70: 905-911. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68: 1387-1394. Disclosure of Interest None Declared</abstract><cop>Kidlington</cop><pub>Elsevier Limited</pub><doi>10.1136/annrheumdis-2012-eular.483</doi></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2013-06, Vol.71, p.665
issn 0003-4967
1468-2060
language eng
recordid cdi_proquest_journals_1777975955
source BMJ Journals - NESLi2
title AB0483 Cutaneous adverse events related to TNF[alpha] blockers in patients with chronic inflammatory arthritis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T20%3A24%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AB0483%20Cutaneous%20adverse%20events%20related%20to%20TNF%5Balpha%5D%20blockers%20in%20patients%20with%20chronic%20inflammatory%20arthritis&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Machado,%20NP&rft.date=2013-06-01&rft.volume=71&rft.spage=665&rft.pages=665-&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2012-eular.483&rft_dat=%3Cproquest%3E4008650261%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777975955&rft_id=info:pmid/&rfr_iscdi=true